Sustiva Once-Daily Anti-HIV Capsules Approved In Europe

July 1999
Worldwide Biotech;Jul99, Vol. 11 Issue 7, p1
Trade Publication
Reports on DuPont Pharmaceuticals Incorporated's anti-HIV drug, Sustiva. Its therapeutic concern and evidence of effectiveness; Its approval and recommendation; Information on Sustiva therapy; Side effects.


Related Articles

  • DuPont receives FDA approval for anti-HIV drug.  // Chemical Market Reporter;09/28/98, Vol. 254 Issue 13, p14 

    Reports on DuPont Pharmaceuticals' receipt of an approval from the United States Food and Drug Administration for its anti-HIV drug product.

  • AIDS drug gets quick OK.  // FDA Consumer;Jan/Feb99, Vol. 33 Issue 1, p2 

    Reports on the approval of efavirenz, manufactured under the trade name Sustiva by DuPont Pharmaceuticals, for the treatment of HIV-1 infection in combination with other HIV drugs. Symptoms that were reported in more than half of patients treated with efavirenz; Need to monitor patients'...

  • Expanded access for Efavirenz.  // AIDS Patient Care & STDs;Dec97, Vol. 11 Issue 6, p457 

    Announces an expanded access program for the antiviral agent, efavirenz (Sustiva, formerly DMP 266) by DuPont Merck. Who use program as of April 1998; Minimum age for participants in program; Exclusions in the program.

  • Contract pricing holds.  // Drug Topics;12/12/94, Vol. 138 Issue 23, p7 

    Reports on the reaction of hospital registered pharmacists on the plan of DuPont Pharma to reintroduce Coumadin, Percocet and Percodan in unit dose. Original plan of the company to phase out the drugs; Prices of the drugs.

  • Prescription drugs filled, labeled in sync. Abrams, Bernard // Packaging Digest;Sep2000, Vol. 37 Issue 10, p42 

    Reports on DuPont Pharmaceuticals' installation of a versatile packaging line at its Garden City, New York operation. Number of prescription drug bottles processed per minute; Performance and prospects for the line; Key considerations in selecting and modifying the equipment; Packaging process.

  • Dupont Group continues expanding. Ruano, Lida Estela // Caribbean Business;2/12/1998, Vol. 26 Issue 6, p8 

    Reports that DuPont-Merck Pharma company and the Swiss Ares-Serona Group manufacturing contract, is enjoying success for the third year, while focusing on the construction of a state of the art building in Puerto Rico, as the company continues to expand. Economic aspects of the project; When...

  • Equivalence, equity & exclusivity. Wechsler, Jill // Pharmaceutical Executive;May98, Vol. 18 Issue 5, p16 

    Focuses on the controversy over the equivalence of narrow therapeutic index (NTI) generics in the United States. Debate over DuPont Merck's link with patient and medical groups to promote adoption of patient notification and consent legislation; Concerns on the antigeneric campaign in the...

  • PHARMA & FINE CHEMICALS: Market Briefs.  // Chemical Market Reporter;06/14/99, Vol. 255 Issue 24, p28 

    Presents news briefs on the pharmaceutical and fine chemicals industry in June 1999. Approval for clobetasol propionate gel of Taro Pharmaceutical Industries Ltd.; Marketing authorization granted by the European Commission to DuPont Pharmaceuticals for its anti-HIV drug; Computer-monitoring...

  • Opioid antagonist for alcohol dependence.  // Modern Medicine;Mar95, Vol. 63 Issue 3, p27 

    Reports on the approval of Naltrexone HCl tablets under the brandname Revia by DuPont Merck Pharmaceutical Co. for the treatment of alcohol dependence by the US Food and Drug Administration. Recommended dosage; Contraindications; Side effects.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics